Navigation auf

Hochschulmedizin Zürich ImmunoPhage


Almost 100 years after the discovery of the first antibiotics, bacterial infections continue to be one of the most challenging health problems and impose a tremendous burden on our health care system. Yet, the common treatment approach still consists of administration of antibiotics. However, this practice causes adverse medical and socioeconomic effects, including the development of antibiotic resistance and disruption of the normal microbiome.

Therefore, eight research groups of the University of Zurich, ETH Zurich, University Hospital Zurich, and Balgrist University Hospital have joined forces to develop a fundamentally new therapeutic option - the "ImmunoPhage" project. The aim is to equip bacteriophages, i.e. viruses that exclusively attack bacteria, with elements that specifically support immune defenses. The combination of antimicrobial activity with immunomodulatory properties of these immunophages forms a generalizable, sustainable and tailored approach for the treatment of bacterial infections, and potentially also inflammatory diseases.

ImmunoPhage has been a HMZ Flagship Project since 2020.

Weiterführende Informationen


Prof. Dr. med. Onur Boyman
University Hospital Zurich
Department of Immunology
Gloriastrasse 23
8091 Zürich

Prof. Dr. med. Thomas Kessler
Balgrist University Hospital
Department of Neuro-Urology
Forchstrasse 340
8008 Zürich

Prof. Dr. Martin Loessner
ETH Zurich
Institute of Food, Nutrition and Health
Schmelzbergstrasse 7
8092 Zürich